{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-26-000013","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.266875+00:00","generated_at":"2026-05-15T06:10:46.924415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"QuidelOrtho prelim Q1 rev $615-620M; weaker respiratory season, China headwinds","bullets":["Prelim Q1 2026 revenue of $615-$620M; U.S. flu-like illness visits down ~30% YoY.","China distributor sales slow on proposed NHSA reimbursement cuts; EMEA orders delayed by Middle East conflict.","Q1 2026 free cash flow guided to negative $(65)-$(70)M; positive full-year still expected.","Low end of FY 2026 guidance remains achievable; full discussion on May 5 earnings call.","Core business (>70% of total rev) remains strong; cost actions underway to drive 2026 performance."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-26-000013","json":"https://secwatch.observer/filing/0001906324-26-000013.json","markdown":"https://secwatch.observer/filing/0001906324-26-000013.md","text":"https://secwatch.observer/filing/0001906324-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632426000013/0001906324-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632426000013/qdel-20260415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:10:46.924415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61f542694a5e2ce6624b81959475e3a791a00078","claim":"QuidelOrtho Corp reported first quarter of 2026, ended March 29, 2026 results: revenue $615-$620 million. Guidance reaffirmed.","evidence_excerpt":"on Tuesday, May 5, 2026, after the market closes. Preliminary Unaudited First Quarter 2026 Revenue The Company currently expects preliminary unaudited revenue, as reported, of $615-$620 million for the first quarter of 2026. This preliminary unaudited revenue was primarily driven by a weaker respiratory season, with U.S. Influenza-like Illness visits down","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632426000013/0001906324-26-000013-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2026, ended March 29, 2026"},{"label":"Revenue","value":"$615-$620 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}